If the potential concerns with Syk inhibitors are on the FDA's radar at all, I'd expect it would be very cautious in granting approval.
In my experience, the FDA tends to look at the clinical data, not theoretical concerns raised by preclinical studies. Of course if there is a cancer signal in the actual data, that would change the FDA's attitude radically.
Market Data 
Markets 
AI
